Get the Stockscreener App
1.33
3.91%
0.05
Telomir Pharmaceuticals Inc stock is traded at $1.33, with a volume of 61,190.
It is up +3.91% in the last 24 hours and up +3.10% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.28
Open:
$1.27
24h Volume:
61,190
Relative Volume:
0.44
Market Cap:
$45.73M
Revenue:
-
Net Income/Loss:
$-10.41M
P/E Ratio:
-3.9572
EPS:
-0.3361
Net Cash Flow:
$-3.69M
1W Performance:
+4.72%
1M Performance:
+3.10%
6M Performance:
-5.00%
1Y Performance:
-69.35%
1-Day Range:
$1.26
$1.33
1-Week Range:
$1.23
$1.33
52-Week Range:
$1.05
$4.55
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.33 | 44.01M | 0 | -10.41M | -3.69M | -0.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Setup Watch: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn
Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart
Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn
Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) details 2025 results, Telomir-1 plans and TELI merger - Stock Titan
US Market Recap: Will Unisys Corporation stock go up in YEAR2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Telomir Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Winners Losers: Is Telomir Pharmaceuticals Inc a top pick in the sectorTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Risk Analysis: Can Genco Shipping Trading Limited be recession proofWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Action: Is Telomir Pharmaceuticals Inc. a good ESG investmentQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Portfolio Recap: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Nasdaq Moves: Is Telomir Pharmaceuticals Inc a good ESG investment2025 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire
TELO Technical Analysis & ETF Price Forecast - Intellectia AI
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Coshocton Tribune
Activity Recap: Is Telomir Pharmaceuticals Inc stock influenced by commodity pricesCPI Data & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Valuation Update: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Selloffs & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines () - aktiencheck.de
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Telomir Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell? - Defense World
Telomir Sets Vote on Transformative TELI Merger and Governance Changes - The Globe and Mail
Telomir reveals promising preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals demonstrates broad tumor cell mortality in human triple-negative breast cancer models - marketscreener.com
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models. - Bitget
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - marketscreener.com
Telomir (NASDAQ: TELO) posts new Telomir-1 preclinical data in triple-negative breast cancer - Stock Titan
Experimental breast cancer drug triggers iron-dependent tumor cell death - Stock Titan
Investment Report: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
What are the risks of holding Telomir Pharmaceuticals Inc.Trade Exit Summary & Entry Point Confirmation Signals - mfd.ru
Is Telomir Pharmaceuticals Inc. a top pick in the sectorTrade Signal Summary & Weekly Momentum Picks - mfd.ru
Will Telomir Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Growth Report & Community Supported Trade Ideas - mfd.ru
John Paul DeJoria holds 9.4% of Telomir (TELO) common stock - Stock Titan
Can Telomir Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Sentiment & Precise Swing Trade Alerts - mfd.ru
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - ACCESS Newswire
What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks
Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - Stock Titan
Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView
Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is Telomir Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
Insider Buy: How does Telomir Pharmaceuticals Inc compare to its peersRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Stock Analysis: How volatile is Telomir Pharmaceuticals Inc stockQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Outlook: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockWeekly Gains Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):